Clinical Distribution Characteristics of 1439 Carbapenem-Resistant Escherichia coli Strains in China: Drug Resistance, Geographical Distribution, Antibiotic MIC50/90

References

• Acevedo R, Bai X, Borrow R, et al. The global meningococcal initiative meeting on prevention of meningococcal disease worldwide: epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations. Expert Rev Vaccines. 2019;18(1):15–30. doi:10.1080/14760584.2019.155752030526162
   PubMed Web of Science ®Google Scholar
• Aracil-García B, Oteo-Iglesias J, Cuevas-Lobato Ó, et al. Rapid increase in resistance to third generation cephalosporins, imipenem and co-resistance in Klebsiella pneumoniae from isolated from 7140 blood-cultures (2010–2014) using EARS-Net data in Spain. Enferm Infecc Microbiol Clin. 2017;35(8):480–486. doi:10.1016/j.eimc.2016.06.00727469416
   PubMed Web of Science ®Google Scholar
• Buetti N, Marschall J, Timsit JF, Atkinson A, Kronenberg A, Sommerstein R. Distribution of pathogens and antimicrobial resistance in bacteraemia according to hospitalization duration: a nationwide surveillance study in Switzerland. Clin Microbiol Infect. 2021. doi:10.1016/j.cmi.2021.04.025
   Web of Science ®Google Scholar
• Polemis M, Tryfinopoulou K, Giakkoupi P, Vatopoulos A. Eight-year trends in the relative isolation frequency and antimicrobial susceptibility among bloodstream isolates from Greek hospitals: data from the Greek electronic system for the surveillance of antimicrobial resistance - WHONET-Greece, 2010 to 2017. Euro Surveill. 2020;25(34). doi:10.2807/1560-7917.ES.2020.25.34.1900516
   Google Scholar
• Liu Y, Li R, Xiao X, Wang Z. Antibiotic adjuvants: an alternative approach to overcome multi-drug resistant Gram-negative bacteria. Crit Rev Microbiol. 2019;45(3):301–314. doi:10.1080/1040841X.2019.159981330985240
   PubMed Web of Science ®Google Scholar
• Mühlberg E, Umstätter F, Kleist C, Domhan C, Mier W, Uhl P. Renaissance of vancomycin: approaches for breaking antibiotic resistance in multidrug-resistant bacteria. Can J Microbiol. 2020;66(1):11–16. doi:10.1139/cjm-2019-030931545906
   PubMed Web of Science ®Google Scholar
• Zhang J, Xu J, Ma H, et al. Designing an amino-fullerene derivative C(70)-(EDA)(8) to fight superbacteria. ACS Appl Mater Interfaces. 2019;11(16):14597–14607. doi:10.1021/acsami.9b0148330938506
   PubMed Web of Science ®Google Scholar
• Wu B, Qi C, Wang L, et al. Detection of microbial aerosols in hospital wards and molecular identification and dissemination of drug resistance of Escherichia coli. Environ Int. 2020;137:105479. doi:10.1016/j.envint.2020.10547932070803
   PubMed Web of Science ®Google Scholar
• Nordmann P, Poirel L. Epidemiology and diagnostics of carbapenem resistance in gram-negative bacteria. Clin Infect Dis. 2019;69(Suppl 7):S521–s528. doi:10.1093/cid/ciz82431724045
   PubMed Web of Science ®Google Scholar
• Doi Y. Treatment options for carbapenem-resistant gram-negative bacterial infections. Clin Infect Dis. 2019;69(Suppl 7):S565–s575. doi:10.1093/cid/ciz83031724043
   PubMed Web of Science ®Google Scholar
• Potter RF, D’Souza AW, Dantas G. The rapid spread of carbapenem-resistant Enterobacteriaceae. Drug Resist Updat. 2016;29:30–46. doi:10.1016/j.drup.2016.09.00227912842
   PubMed Web of Science ®Google Scholar
• Freeman R, Moore LS, Charlett A, Donaldson H, Holmes AH. Exploring the epidemiology of carbapenem-resistant Gram-negative bacteria in west London and the utility of routinely collected hospital microbiology data. J Antimicrob Chemother. 2015;70(4):1212–1218. doi:10.1093/jac/dku50025525198
   PubMed Web of Science ®Google Scholar
• Fritzenwanker M, Imirzalioglu C, Herold S, Wagenlehner FM, Zimmer KP, Chakraborty T. Treatment options for carbapenem- resistant gram-negative infections. Dtsch Arztebl Int. 2018;115(20–21):345–352. doi: 10.3238/arztebl.2018.034529914612
   PubMed Web of Science ®Google Scholar
• Wang Q, Wang X, Wang J, et al. Phenotypic and genotypic characterization of carbapenem-resistant Enterobacteriaceae: data from a longitudinal large-scale CRE Study in China (2012–2016). Clin Infect Dis. 2018;67(suppl_2):S196–s205. doi:10.1093/cid/ciy66030423057
   PubMed Web of Science ®Google Scholar
• Cassini A, Högberg LD, Plachouras D, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19(1):56–66. doi:10.1016/S1473-3099(18)30605-430409683
   PubMed Web of Science ®Google Scholar
• Peri AM, Doi Y, Potoski BA, Harris PNA, Paterson DL, Righi E. Antimicrobial treatment challenges in the era of carbapenem resistance. Diagn Microbiol Infect Dis. 2019;94(4):413–425. doi:10.1016/j.diagmicrobio.2019.01.02030905487
   PubMed Web of Science ®Google Scholar
• Wenzler E, Scoble PJ. An appraisal of the pharmacokinetic and pharmacodynamic properties of meropenem-vaborbactam. Infect Dis Ther. 2020;9(4):769–784. doi:10.1007/s40121-020-00344-z33025557
   PubMed Web of Science ®Google Scholar
• Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis. 2017;215(suppl_1):S28–s36. doi:10.1093/infdis/jiw28228375512
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Trecarichi EM, Corona A, et al. Efficacy of Ceftazidime-Avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae. Clin Infect Dis. 2019;68(3):355–364. doi:10.1093/cid/ciy49229893802
   PubMed Web of Science ®Google Scholar
• Ripabelli G, Sammarco ML, Scutellà M, Felice V, Tamburro M. Carbapenem-resistant KPC- and TEM-producing Escherichia coli ST131 isolated from a hospitalized patient with urinary tract infection: first isolation in Molise Region, Central Italy, July 2018. Microb Drug Resist. 2020;26(1):38–45. doi:10.1089/mdr.2019.008531386590
   PubMed Web of Science ®Google Scholar
• Welker S, Boutin S, Miethke T, Heeg K, Nurjadi D. Emergence of carbapenem-resistant ST131 Escherichia coli carrying bla (OXA-244) in Germany, 2019 to 2020. Euro Surveill. 2020;25(46). doi:10.2807/1560-7917.ES.2020.25.46.2001815
   Google Scholar
• Wayne P. The Clinical and Laboratory Standards Institute antimicrobial susceptibility testing standards. CLSI. 2019;3:M100–ED29.
   Google Scholar
• Diallo OO, Baron SA, Abat C, Colson P, Chaudet H, Rolain JM. Antibiotic resistance surveillance systems: a review. J Glob Antimicrob Resist. 2020;23:430–438. doi:10.1016/j.jgar.2020.10.00933176216
   PubMed Web of Science ®Google Scholar
• Patil S, Chen H, Zhang X, Lian M, Ren PG, Wen F. Antimicrobial resistance and resistance determinant insights into multi-drug resistant gram-negative bacteria isolates from paediatric patients in China. Infect Drug Resist. 2019;12:3625–3634. doi:10.2147/IDR.S22373631819545
   PubMed Web of Science ®Google Scholar
• Spaziante M, Venditti C, Butera O, et al. Importance of surveillance of new delhi metallo-beta-lactamase Klebsiella pneumoniae: molecular characterization and clonality of strains isolated in the Lazio Region, Italy. Infect Drug Resist. 2021;14:3659–3665. doi:10.2147/IDR.S31871734526785
   PubMed Web of Science ®Google Scholar
• Wang YLH, Zhang L, Sun B. Application of modified carbapenem inactivation method and its derivative tests for the detection of carbapenemase-producing Aeromonas. Infect Drug Resist. 2021;2021(14):3949–3960. doi: 10.2147/IDR.S330115
   Web of Science ®Google Scholar
• El-Badawy MF, Abdelwahab SF, Alghamdi SA, Shohayeb MM. Characterization of phenotypic and genotypic traits of carbapenem-resistant Acinetobacter baumannii clinical isolates recovered from a tertiary care hospital in Taif, Saudi Arabia. Infect Drug Resist. 2019;12:3113–3124. doi:10.2147/IDR.S20669131632100
   PubMed Web of Science ®Google Scholar
• Cheng P, Li F, Liu R, et al. Prevalence and molecular epidemiology characteristics of carbapenem-resistant Escherichia coli in Heilongjiang Province, China. Infect Drug Resist. 2019;12:2505–2518. doi:10.2147/IDR.S20812231496764
   PubMed Web of Science ®Google Scholar
• Pruthvishree BS, Vinodh Kumar OR, Sinha DK, et al. Spatial molecular epidemiology of carbapenem-resistant and New Delhi metallo beta-lactamase (blaNDM)-producing Escherichia coli in the piglets of organized farms in India. J Appl Microbiol. 2017;122(6):1537–1546. doi:10.1111/jam.1345528345184
   PubMed Web of Science ®Google Scholar
• Gurung S, Kafle S, Dhungel B, et al. Detection of OXA-48 gene in carbapenem-resistant Escherichia coli and Klebsiella pneumoniae from urine samples. Infect Drug Resist. 2020;13:2311–2321. doi:10.2147/IDR.S25996732765007
   PubMed Web of Science ®Google Scholar
• Guh AY, Bulens SN, Mu Y, et al. Epidemiology of carbapenem-resistant Enterobacteriaceae in 7 US communities, 2012–2013. JAMA. 2015;314(14):1479–1487. doi:10.1001/jama.2015.1248026436831
   PubMed Web of Science ®Google Scholar
• Johnson JK, Robinson GL, Pineles LL, et al. Carbapenem MICs in Escherichia coli and Klebsiella species producing extended-spectrum β-lactamases in critical care patients from 2001 to 2009. Antimicrob Agents Chemother. 2017;61(4). doi:10.1128/AAC.01718-16
   Web of Science ®Google Scholar
• Tang X, Xiao M, Zhuo C, Xu Y, Zhong N. Multi-level analysis of bacteria isolated from inpatients in respiratory departments in China. J Thorac Dis. 2018;10(5):2666–2675. doi:10.21037/jtd.2018.04.4629997928
   PubMed Web of Science ®Google Scholar
• Hu FP, Guo Y, Zhu DM, et al. Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005–2014. Clin Microbiol Infect. 2016;22(Suppl 1):S9–14. doi:10.1016/j.cmi.2016.01.00127000156
   PubMed Web of Science ®Google Scholar
• Johnston BD, Thuras P, Porter SB, et al. Activity of cefiderocol, ceftazidime-avibactam, and eravacycline against carbapenem-resistant Escherichia coli isolates from the United States and international sites in relation to clonal background, resistance genes, coresistance, and region. Antimicrob Agents Chemother. 2020;64(10):451. doi:10.1128/AAC.00797-20
   Web of Science ®Google Scholar
• Garcia-Effron G. Rezafungin-mechanisms of action, susceptibility and resistance: similarities and differences with the other echinocandins. J Fungi (Basel). 2020;6(4):67. doi: 10.3390/jof6040262
   Google Scholar
• Alatoom A, Elsayed H, Lawlor K, et al. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Int J Infect Dis. 2017;62:39–43. doi:10.1016/j.ijid.2017.06.00728610832
   PubMed Web of Science ®Google Scholar